Tillman Gerngross passes the Adimab baton after 15 years, moving from CEO to executive chairman role

Amber Tong

Senior Editor

A new era is unfolding at Adimab.

Fifteen years after he co-founded the antibody discovery shop, Tillman Gerngross is stepping down as CEO — handing the reins to Philip Chase, general counsel. Stepping away from day-to-day operations, the company noted he will now move to the strategic role of executive chairman of the board.

It’s the second departure for Gerngross within the past few months. Back in February, the longtime Dartmouth professor resigned from the CEO post at Adagio, the Covid-focused Adimab spinout.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Tillman Gerngross passes the Adimab baton after 15 years, moving from CEO to executive chairman role

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Roche's Genentech touts label expansion for blockbuster lung cancer drug Alecensa

Till­man Gern­gross pass­es the Adimab ba­ton af­ter 15 years, mov­ing from CEO to ex­ec­u­tive chair­man role

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Roche's Genen­tech touts la­bel ex­pan­sion for block­buster lung can­cer drug Ale­cen­sa

Tillman Gerngross passes the Adimab baton after 15 years, moving from CEO to executive chairman role

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Roche's Genentech touts label expansion for blockbuster lung cancer drug Alecensa